DOSE REDUCTION OF A CANNABINOID CB1 RECEPTOR ANTAGONIST IN THE TREATMENT OF OVERWEIGHT OR OBESITY

DOSE REDUCTION OF A CANNABINOID CB1 RECEPTOR ANTAGONIST IN THE TREATMENT OF OVERWEIGHT OR OBESITY

O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce the unfavourable psychiatric side e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SZILVASSY, ZOLTAN, FLEMING, ALEXANDER G, BROWNSTEIN, MIKE, TORY, KALMAN, ROTH, JESSE, EGRI, JANOS, LITERATI NAGY, PETER, BERNATH, SANDOR, KOLONICS, ATTILA, VIGH, LASZLO
Format: Patent
Sprache:eng ; fre
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce the unfavourable psychiatric side effect of the latter. L'amidoxime O-(3-pipéridino-2-hydroxy-1-propyl)-nicotinique ou sur un sel d'addition avec les acides pharmaceutiquement acceptables de celle-ci est administré à des patients souffrant de surpoids ou d'obésité et traité par un antagoniste des récepteurs cannabinoïdes CB1 tels que le rimonabant pour réduire l'effet secondaire psychiatrique défavorable de ce dernier.